<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Anti-platelet integrin GPIIIa49-66 antibody (Ab) induces complement-independent platelet oxidative fragmentation and <z:hpo ids='HP_0011420'>death</z:hpo> by generation of platelet <z:chebi fb="39" ids="44785">peroxide</z:chebi> following <z:chebi fb="1" ids="16474">NADPH</z:chebi> oxidase activation </plain></SENT>
<SENT sid="1" pm="."><plain>A C-terminal 385-amino acid fragment of ADAMTS-18 (a disintegrin metalloproteinase with thrombospondin motifs produced in endothelial cells) induces oxidative platelet fragmentation in an identical kinetic fashion as anti-GPIIIa49-66 Ab </plain></SENT>
<SENT sid="2" pm="."><plain>Endothelial cell ADAMTS-18 secretion is enhanced by thrombin and activated by thrombin cleavage to fragment platelets </plain></SENT>
<SENT sid="3" pm="."><plain>Platelet aggregates produced ex vivo with <z:chebi fb="13" ids="16761">ADP</z:chebi> or collagen and fibrinogen are destroyed by the C-terminal ADAMTS-18 fragment </plain></SENT>
<SENT sid="4" pm="."><plain>Anti-ADAMTS-18 Ab shortens the tail vein <z:mp ids='MP_0001914'>bleeding</z:mp> time </plain></SENT>
<SENT sid="5" pm="."><plain>The C-terminal fragment protects against FeCI3-induced carotid artery <z:mp ids='MP_0005048'>thrombosis</z:mp> as well as <z:e sem="disease" ids="C0007785" disease_type="Disease or Syndrome" abbrv="">cerebral infarction</z:e> in a postischemic <z:hpo ids='HP_0001297'>stroke</z:hpo> model </plain></SENT>
<SENT sid="6" pm="."><plain>Thus, a new mechanism is proposed for platelet <z:e sem="disease" ids="C0302148,C0087086" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">thrombus</z:e> clearance, via platelet oxidative fragmentation induced by thrombin cleavage of ADAMTS-18 </plain></SENT>
</text></document>